Saturday 17 October 2026
Export CYAD’s income statement to Excel — free account
Celyad SA
CYAD Healthcare Biotechnology
Celyad SA’s revenue for fiscal 2025 (year ended December 2025) was $23,800.00, down 88.2% from fiscal 2024.
Follow CYAD
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.88 | 0.40 | 2.99 | 1.16 | |
Current Ratio |
0.94 | 0.66 | 3.59 | 1.26 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 13.23% | 6.49% | 2.88% | |
Debt/Equity |
0.00 | (0.24) | 0.26 | 0.34 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 2.52 | |
Intangible Assets out of Total Assets |
0.01 | 0.06 | 0.04 | 0.05 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (3.72) | (3.05) | (7.99) | |
Working Capital |
(0.07) | (1.43) | 6.73 | 1.75 | |
Capital Expenditures |
— | — | (0.13) | 1.09 | |
Net Current Asset Value |
(0.23) | (7.20) | (0.99) | (3.78) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.07 | 2.30 | 2.42 | 2.47 | |
Average Payables |
2.65 | 3.72 | 3.66 | 5.62 | |
Average Assets |
11.84 | 36.83 | 45.75 | 52.06 | |
Average Common Equity |
(5.82) | 186.45 | 22.23 | 15.90 |
Columns are period end dates · fundamentals updated 14 Oct 2026